{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:41:08Z","timestamp":1788050468383,"version":"build-2784847793"},"reference-count":136,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,3,30]],"date-time":"2025-03-30T00:00:00Z","timestamp":1743292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Chemotherapy-induced neutropenia (CIN) and chemotherapy-induced alopecia (CIA) are significant toxicities affecting cancer patients. CIN is a potentially fatal complication of chemotherapy caused by myelosuppression and increased infection susceptibility, while CIA, although not fatal, severely affects treatment adherence and mental health. This study provides a comprehensive comparative analysis of CIN and CIA, focusing on patient, disease, treatment, and genetic risk factors. Key risk factors for CIN and CIA include age, poor performance status, body mass index (BMI), laboratory abnormalities, and pre-existing comorbidities. Both toxicities were significantly associated with breast cancer patients, although CIN patients were more likely to have hematological cancer, and CIA patients were more likely to have solid tumors. Notably, anthracyclines, alkylators, and taxanes frequently induce both toxicities, although their timelines and clinical implications differed. There was no clear overlap between genetic predispositions and toxicities beyond single-nucleotide polymorphisms (SNPs) in the ABCB1 gene. This is the first study to directly compare CIN and CIA, offering insights into personalized oncology care. Understanding the risk factors implicated in the development of CIN and CIA will enable physicians to manage patient outcomes.<\/jats:p>","DOI":"10.3390\/cancers17071163","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T01:59:36Z","timestamp":1743386376000},"page":"1163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia"],"prefix":"10.3390","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5173-0698","authenticated-orcid":false,"given":"Simonetta I.","family":"Gaumond","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4255-8355","authenticated-orcid":false,"given":"Karen J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peyton V.","family":"Warp","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Kamholtz","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilee M.","family":"Dreifus","sequence":"additional","affiliation":[{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Jimenez","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL 33136, USA"},{"name":"Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33136, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,3,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/cncr.11882","article-title":"Chemotherapy-Induced Neutropenia","volume":"100","author":"Crawford","year":"2004","journal-title":"Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00520-010-0840-y","article-title":"Risk Factors for Chemotherapy-Induced Neutropenia Occurrence in Breast Cancer Patients: Data from the INC-EU Prospective Observational European Neutropenia Study","volume":"19","author":"Schwenkglenks","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1523-5394.2001.96007.x","article-title":"Psychological Sequelae and Alopecia among Women with Cancer","volume":"9","author":"McGarvey","year":"2001","journal-title":"Cancer Pract."},{"key":"ref_4","unstructured":"National Cancer Institute (2025, March 27). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/jocd.12308","article-title":"Chemotherapy-Induced Alopecia Management: Clinical Experience and Practical Advice","volume":"16","author":"Rossi","year":"2017","journal-title":"J. Cosmet. Dermatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1346-8138.1998.tb02507.x","article-title":"Principles of Hair Cycle Control","volume":"25","author":"Paus","year":"1998","journal-title":"J. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/ijd.13906","article-title":"Pathogenesis and Treatment Options for Chemotherapy-Induced Alopecia: A Systematic Review","volume":"57","author":"Fortman","year":"2018","journal-title":"Int. J. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1191\/1078155201jp084oa","article-title":"Predictors for Chemotherapy-Related Severe or Febrile Neutropenia: A Review of the Clinical Literature","volume":"7","author":"Lawless","year":"2001","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk Factors for Febrile Neutropenia among Patients with Cancer Receiving Chemotherapy: A Systematic Review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. Oncol.\/Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.leukres.2012.02.002","article-title":"The Need for Improved Neutropenia Risk Assessment in DLBCL Patients Receiving R-CHOP-21: Findings from Clinical Practice","volume":"36","author":"Salar","year":"2012","journal-title":"Leuk. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1080\/1042819031000119262","article-title":"Risk of Febrile Neutropenia among Patients with Intermediate-Grade Non-Hodgkin\u2019s Lymphoma Receiving CHOP Chemotherapy","volume":"44","author":"Lyman","year":"2003","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/j.1365-2141.2008.07514.x","article-title":"Multivariate Analysis of Febrile Neutropenia Occurrence in Patients with Non-Hodgkin Lymphoma: Data from the INC-EU Prospective Observational European Neutropenia Study","volume":"144","author":"Pettengell","year":"2009","journal-title":"Br. J. Haematol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","article-title":"Predictors of Severe and Febrile Neutropenia during Primary Chemotherapy for Ovarian Cancer","volume":"125","author":"Laskey","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/(SICI)1097-0142(20000215)88:4<796::AID-CNCR10>3.0.CO;2-P","article-title":"The Predictive Value of Body Protein for Chemotherapy-Induced Toxicity","volume":"88","author":"Aslani","year":"2000","journal-title":"Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/sj.bjc.6600724","article-title":"Baseline and Early Lymphopenia Predict for the Risk of Febrile Neutropenia after Chemotherapy","volume":"88","author":"Borg","year":"2003","journal-title":"Br. J. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00280-007-0648-8","article-title":"Logistic Regression Analysis for Febrile Neutropenia (FN) Induced by Docetaxel in Japanese Cancer Patients","volume":"62","author":"Ozawa","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1093\/annonc\/mdl321","article-title":"Relationship between Cytochrome 3A Activity, Inflammatory Status and the Risk of Docetaxel-Induced Febrile Neutropenia: A Prospective Study","volume":"18","author":"Alexandre","year":"2007","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.2000.18.2.325","article-title":"Factors That Predict Chemotherapy-Induced Myelosuppression in Lymphoma Patients: Role of the Tumor Necrosis Factor Ligand-Receptor System","volume":"18","author":"Voog","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1002\/cncr.11827","article-title":"Risk and Timing of Hospitalization for Febrile Neutropenia in Patients Receiving CHOP, CHOP-R, or CNOP Chemotherapy for Intermediate-Grade Non-Hodgkin Lymphoma","volume":"98","author":"Lyman","year":"2003","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2354.2009.01121.x","article-title":"Risk Assessment Model for First-Cycle Chemotherapy-Induced Neutropenia in Patients with Solid Tumours","volume":"19","author":"Iglesias","year":"2010","journal-title":"Eur. J. Cancer Care"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/annonc\/mdn655","article-title":"A General Chemotherapy Myelotoxicity Score to Predict Febrile Neutropenia in Hematological Malignancies","volume":"20","author":"Moreau","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1007\/s00520-011-1241-6","article-title":"Incidence of Febrile Neutropenia among Early-Stage Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy","volume":"20","author":"Chan","year":"2012","journal-title":"Support Care Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1200\/JCO.2000.18.16.3038","article-title":"The Multinational Association for Supportive Care in Cancer Risk Index: A Multinational Scoring System for Identifying Low-Risk Febrile Neutropenic Cancer Patients","volume":"18","author":"Klastersky","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"351","DOI":"10.3109\/10428190009089435","article-title":"A Predictive Model for Life-Threatening Neutropenia and Febrile Neutropenia after the First Course of CHOP Chemotherapy in Patients with Aggressive Non-Hodgkin\u2019s Lymphoma","volume":"37","author":"Intragumtornchai","year":"2000","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"681","DOI":"10.3889\/oamjms.2022.8448","article-title":"Malnutrition as Risk Factor for Febrile Neutropenia in Children with Acute Lymphoblastic Leukemia","volume":"10","author":"Hanzelina","year":"2022","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Xiao, A.T., Tong, Y.X., Xu, X.S., Zhou, Y., and Zhang, S. (2020). Preoperative Nutritional Status Contributes to the Development of Neutropenia Event in Patients with Gastric Cancer Receiving CAPEOX Adjuvant Chemotherapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00692"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s00520-024-08780-0","article-title":"Effects of Nutritional Interventions on Cancer Patients Receiving Neoadjuvant Chemoradiotherapy: A Meta-Analysis of Randomized Controlled Trials","volume":"32","author":"Li","year":"2024","journal-title":"Support Care Cancer"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.clnu.2011.11.002","article-title":"Randomized Study of Clinical Effect of Enteral Nutrition Support during Neoadjuvant Chemotherapy on Chemotherapy-Related Toxicity in Patients with Esophageal Cancer","volume":"31","author":"Miyata","year":"2012","journal-title":"Clin. Nutr."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1002\/cncr.20484","article-title":"Effect of Vitamin B12, Folate, and Dietary Supplements on Breast Carcinoma Chemotherapy\u2013Induced Mucositis and Neutropenia","volume":"101","author":"Branda","year":"2004","journal-title":"Cancer"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3816\/SCT.2005.n.023","article-title":"Final Results of a Placebo-Controlled Study of Filgrastim in Small-Cell Lung Cancer: Exploration of Risk Factors for Febrile Neutropenia","volume":"3","author":"Crawford","year":"2005","journal-title":"Support Cancer Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.2004.03.213","article-title":"Incidence and Predictors of Low Chemotherapy Dose-Intensity in Aggressive Non-Hodgkin\u2019s Lymphoma: A Nationwide Study","volume":"22","author":"Lyman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","article-title":"History of Chronic Comorbidity and Risk of Chemotherapy-Induced Febrile Neutropenia in Cancer Patients Not Receiving G-CSF Prophylaxis","volume":"25","author":"Chao","year":"2014","journal-title":"Ann. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.lungcan.2020.01.004","article-title":"Predicting Risk of Chemotherapy-Induced Severe Neutropenia: A Pooled Analysis in Individual Patients Data with Advanced Lung Cancer","volume":"141","author":"Cao","year":"2020","journal-title":"Lung Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1093\/annonc\/mdn560","article-title":"Pretreatment Haematological Laboratory Values Predict for Excessive Myelosuppression in Patients Receiving Adjuvant FEC Chemotherapy for Breast Cancer","volume":"20","author":"Jenkins","year":"2009","journal-title":"Ann. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e1143","DOI":"10.1002\/onco.13811","article-title":"Evaluation of the Association of Polymorphisms with Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2\/-3","volume":"26","author":"Iwata","year":"2021","journal-title":"Oncologist"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1200\/JCO.1996.14.2.636","article-title":"Early Lymphopenia after Cytotoxic Chemotherapy as a Risk Factor for Febrile Neutropenia","volume":"14","author":"Blay","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s00520-010-0821-1","article-title":"Development and Validation of a Prediction Model for the Risk of Developing Febrile Neutropenia in the First Cycle of Chemotherapy among Elderly Patients with Breast, Lung, Colorectal, and Prostate Cancer","volume":"19","author":"Hosmer","year":"2011","journal-title":"Support Care Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1078155215603229","article-title":"Comorbidities among Patients with Cancer Who Do and Do Not Develop Febrile Neutropenia during the First Chemotherapy Cycle","volume":"22","author":"Li","year":"2016","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1159\/000321545","article-title":"Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin\u2019s Lymphoma Patients Receiving Pegfilgrastim","volume":"125","author":"Ng","year":"2010","journal-title":"Acta Haematol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3816\/CLM.2001.n.011","article-title":"The Impact of Age on Delivered Dose Intensity and Hospitalizations for Febrile Neutropenia in Patients with Intermediate-Grade Non-Hodgkin\u2019s Lymphoma Receiving Initial CHOP Chemotherapy: A Risk Factor Analysis","volume":"2","author":"Morrison","year":"2001","journal-title":"Clin. Lymphoma"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"5154","DOI":"10.1182\/blood-2022-165527","article-title":"Inpatient Burden and Clinical Outcomes of Febrile Neutropenia in Cancer Patients: A National Inpatient Sample Database Analysis","volume":"140","author":"Makhani","year":"2022","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1086\/383050","article-title":"Management of Fever in Neutropenic Patients with Different Risks of Complications","volume":"39","author":"Klastersky","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/OP.21.00148","article-title":"Risk-Stratifying Treatment Strategies for Febrile Neutropenia-Tools, Tools Everywhere, and Not a Single One That Works?","volume":"17","author":"Wijeratne","year":"2021","journal-title":"JCO Oncol. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.bjhh.2014.11.012","article-title":"Results of High-Risk Neutropenia Therapy of Hematology\u2013Oncology Patients in a University Hospital in Uruguay","volume":"37","author":"Guadagna","year":"2015","journal-title":"Rev. Bras. Hematol. Hemoter."},{"key":"ref_45","first-page":"825","article-title":"Management of Neutropenia in Cancer Patients","volume":"10","author":"Lustberg","year":"2012","journal-title":"Clin. Adv. Hematol. Oncol. H&O"},{"key":"ref_46","unstructured":"Seiter, K. (2025, March 27). Acute Myeloid Leukemia (AML) Treatment Protocols: Treatment Protocols. Available online: https:\/\/emedicine.medscape.com\/article\/2004793-overview?form=fpf."},{"key":"ref_47","unstructured":"Chennamadhavuni, A., Lyengar, V., Mukkamalla, S.K.R., and Shimanovsky, A. (2025). Leukemia. StatPearls, StatPearls Publishing."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"333","DOI":"10.3109\/10428199609051627","article-title":"Bone Marrow Involvement, in Intensively Treated Patients with Intermediate Grade Non-Hodgkin\u2019s Lymphoma, Is a Risk Factor for Granulocytopenia and Fever","volume":"20","author":"Lishner","year":"1996","journal-title":"Leuk. Lymphoma"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3892\/ol.2023.13918","article-title":"Clinical Features and Treatment of Bone Marrow Metastasis","volume":"26","author":"Yang","year":"2023","journal-title":"Oncol. Lett."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Bachlitzanaki, M., Aletras, G., Bachlitzanaki, E., Messaritakis, I., Koukias, S., Koulouridi, A., Bachlitzanakis, E., Kaloeidi, E., Vakonaki, E., and Kontopodis, E. (2023). Evaluation of Febrile Neutropenia in Hospitalized Patients with Neoplasia Undergoing Chemotherapy. Microorganisms, 11.","DOI":"10.3390\/microorganisms11102547"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1200\/JOP.2014.001492","article-title":"Risk and Consequences of Chemotherapy-Induced Febrile Neutropenia in Patients with Metastatic Solid Tumors","volume":"11","author":"Weycker","year":"2015","journal-title":"J. Oncol. Pract."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1200\/JCO.2001.19.5.1320","article-title":"Phase II Trial of Paclitaxel and Carboplatin in Metastatic Small-Cell Lung Cancer: A Groupe Fran\u00e7ais de Pneumo-Canc\u00e9rologie Study","volume":"19","author":"Thomas","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2007.14.9807","article-title":"Phase III Study of Valspodar (PSC 833) Combined with Paclitaxel and Carboplatin Compared with Paclitaxel and Carboplatin Alone in Patients with Stage IV or Suboptimally Debulked Stage III Epithelial Ovarian Cancer or Primary Peritoneal Cancer","volume":"26","author":"Joly","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1038\/sj.bjc.6605270","article-title":"Prevention of Febrile Neutropenia: Use of Prophylactic Antibiotics","volume":"101","author":"Cullen","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1200\/JCO.2000.18.5.1012","article-title":"\u201cLow-Risk\u201d Prediction Rule for Pediatric Oncology Patients Presenting with Fever and Neutropenia","volume":"18","author":"Klaassen","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.clml.2011.11.001","article-title":"How to Manage Neutropenia in Multiple Myeloma","volume":"12","author":"Palumbo","year":"2012","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"285","DOI":"10.31557\/apjcc.2022.7.2.285-293","article-title":"Risk Factors Predicting Chemotherapy-Induced Severe Neutropenia and Outcome in Advanced Stage Non-Small Cell Lung Cancer: Data from the Limited Resource in Thailand","volume":"7","author":"Neesanun","year":"2022","journal-title":"Asian Pac. J. Cancer Care"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"379","DOI":"10.14740\/wjon1530","article-title":"Advanced Stage Is a Risk for Severe Neutropenia in Breast Cancer Patients Undergoing Neoadjuvant Adriamycin\/Cyclophosphamide\/Docetaxel Chemotherapy","volume":"13","author":"Moro","year":"2022","journal-title":"World J. Oncol."},{"key":"ref_59","first-page":"11","article-title":"The Timing of Chemotherapy-Induced Neutropenia and Its Clinical and Economic Impact","volume":"20","author":"Ozer","year":"2006","journal-title":"Oncology"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1002\/cncr.25691","article-title":"Predicting Individual Risk of Neutropenic Complications in Patients Receiving Cancer Chemotherapy","volume":"117","author":"Lyman","year":"2011","journal-title":"Cancer"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3111\/13696990903238603","article-title":"Impact of Primary Prophylaxis on Febrile Neutropenia within Community Practices in the US","volume":"12","author":"Hershman","year":"2009","journal-title":"J. Med. Econ."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.3332\/ecancer.2023.1618","article-title":"The Occurrence and Risk Factors of Chemotherapy-Induced Neutropenia in Patients with Breast Cancer Not Receiving Primary G-CSF Prophylaxis","volume":"17","author":"Hutajulu","year":"2023","journal-title":"Ecancermedicalscience"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"97","DOI":"10.14449\/jbd.2019.7.2.97","article-title":"Incidence of Febrile Neutropenia in Advanced Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy in Korea and Its Impact on Prognosis","volume":"7","author":"Park","year":"2020","journal-title":"J. Breast Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"10263","DOI":"10.7314\/APJCP.2014.15.23.10263","article-title":"Risk of Treatment Related Death and Febrile Neutropaenia with First Line Palliative Chemotherapy for de Novo Metastatic Breast Cancer in Clinical Practice in a Middle Resource Country","volume":"15","author":"Phua","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/S1470-2045(14)70049-X","article-title":"Carboplatin plus Paclitaxel Once a Week versus Every 3 Weeks in Patients with Advanced Ovarian Cancer (MITO-7): A Randomised, Multicentre, Open-Label, Phase 3 Trial","volume":"15","author":"Pignata","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.6004\/jnccn.2017.7010","article-title":"Risk of Febrile Neutropenia Associated with Select Myelosuppressive Chemotherapy Regimens in a Large Community-Based Oncology Practice","volume":"15","author":"Li","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_67","first-page":"3517","article-title":"ABCB1 Polymorphism as a Predictive Biomarker for Amrubicin-Induced Neutropenia","volume":"34","author":"Takakuwa","year":"2014","journal-title":"Anticancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.dmpk.2014.09.009","article-title":"Relationship between ABCB1 Gene Polymorphisms and Severe Neutropenia in Patients with Breast Cancer Treated with Doxorubicin\/Cyclophosphamide Chemotherapy","volume":"30","author":"Ikeda","year":"2015","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"e455","DOI":"10.1093\/oncolo\/oyad304","article-title":"Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients","volume":"29","author":"Lai","year":"2024","journal-title":"Oncologist"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Maeda, A., Matsuo, K., Ando, H., Morishige, J.-I., Muro, K., Uchida, K., and Tajika, M. (2024). Impact of ABCB1 Single-Nucleotide Variants on Early, Extremely Severe Neutropenia Induced by Paclitaxel\/Nanoparticle Albumin-Bound Paclitaxel in Patients with Gastric Cancer. Br. J. Clin. Pharmacol.","DOI":"10.1111\/bcp.16359"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1200\/JCO.2009.21.7943","article-title":"Pharmacogenetic Predictors of Adverse Events and Response to Chemotherapy in Metastatic Colorectal Cancer: Results from North American Gastrointestinal Intergroup Trial N9741","volume":"28","author":"McLeod","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s00280-014-2405-0","article-title":"Associations between UGT1A1*6 or UGT1A1*6\/*28 Polymorphisms and Irinotecan-Induced Neutropenia in Asian Cancer Patients","volume":"73","author":"Han","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2015.23","article-title":"Clinical Validity of New Genetic Biomarkers of Irinotecan Neutropenia: An Independent Replication Study","volume":"16","author":"Crona","year":"2016","journal-title":"Pharmacogenom. J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1159\/000360785","article-title":"MDM2 Rs2279744 and TP53 Rs1042522 Polymorphisms Associated with Etoposide- and Cisplatin-Induced Grade III\/IV Neutropenia in Chinese Extensive-Stage Small-Cell Lung Cancer Patients","volume":"37","author":"Wang","year":"2014","journal-title":"Oncol. Res. Treat."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s10549-011-1637-5","article-title":"MDM2 SNP309 and TP53 R72P Associated with Severe and Febrile Neutropenia in Breast Cancer Patients Treated with 5-FU\/Epirubicin\/Cyclophosphamide","volume":"132","author":"Okishiro","year":"2012","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.2217\/pgs-2015-0005","article-title":"Influx Transporter Variants as Predictors of Cancer Chemotherapy-Induced Toxicity: Systematic Review and Meta-Analysis","volume":"17","author":"Singer","year":"2016","journal-title":"Pharmacogenomics"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1200\/JCO.2008.20.6300","article-title":"Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics","volume":"27","author":"Innocenti","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Bidadi, B., Liu, D., Kalari, K.R., Rubner, M., Hein, A., Beckmann, M.W., Rack, B., Janni, W., Fasching, P.A., and Weinshilboum, R.M. (2018). Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00158"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.31557\/APJCP.2024.25.6.1977","article-title":"The Effect of CYP2C19*2 (Rs4244285) and CYP17 (Rs743572) SNPs on Adriamycin and Paclitaxel Based Chemotherapy Outcomes in Breast Cancer Patients","volume":"25","author":"Gudur","year":"2024","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1007\/s00280-012-1872-4","article-title":"An SNP in CYP39A1 Is Associated with Severe Neutropenia Induced by Docetaxel","volume":"69","author":"Uchiyama","year":"2012","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1007\/s00280-023-04538-3","article-title":"Advanced Statistics Identification of Participant and Treatment Predictors Associated with Severe Adverse Effects Induced by Fluoropyrimidine-Based Chemotherapy","volume":"91","author":"Korver","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4294","DOI":"10.1002\/cam4.5299","article-title":"Association between a Single Nucleotide Polymorphism in the R3HCC1 Gene and Irinotecan Toxicity","volume":"12","author":"Kanesada","year":"2023","journal-title":"Cancer Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"823","DOI":"10.4143\/crt.2017.351","article-title":"APEX1 Polymorphism and Mercaptopurine-Related Early Onset Neutropenia in Pediatric Acute Lymphoblastic Leukemia","volume":"50","author":"Kim","year":"2018","journal-title":"Cancer Res. Treat."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1158\/1078-0432.CCR-15-0964","article-title":"Using Whole-Exome Sequencing to Identify Genetic Markers for Carboplatin and Gemcitabine-Induced Toxicities","volume":"22","author":"Hasmats","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1093\/annonc\/mdt008","article-title":"Genetic Variability in the Multidrug Resistance Associated Protein-1 (ABCC1\/MRP1) Predicts Hematological Toxicity in Breast Cancer Patients Receiving (Neo-)Adjuvant Chemotherapy with 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC)","volume":"24","author":"Vulsteke","year":"2013","journal-title":"Ann. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1634\/theoncologist.2010-0033","article-title":"Effects of Mannose-Binding Lectin Polymorphisms on Irinotecan-Induced Febrile Neutropenia","volume":"15","author":"Sparreboom","year":"2010","journal-title":"Oncologist"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2011.02.026","article-title":"Chemotherapy-Induced Alopecia","volume":"67","author":"Chon","year":"2012","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e50","DOI":"10.1016\/S1470-2045(12)70553-3","article-title":"Pathobiology of Chemotherapy-Induced Hair Loss","volume":"14","author":"Paus","year":"2013","journal-title":"Lancet Oncol."},{"key":"ref_89","first-page":"110","article-title":"Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients with Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials","volume":"18","year":"2019","journal-title":"Clin. Color. Cancer"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ejon.2012.06.003","article-title":"A Comparison of Men and Women\u2019s Experiences of Chemotherapy-Induced Alopecia","volume":"17","author":"Can","year":"2013","journal-title":"Eur. J. Oncol. Nurs."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Arrieta, O., Michel Ortega, R.M., Villanueva-Rodr\u00edguez, G., Serna-Thom\u00e9, M.G., Flores-Estrada, D., Diaz-Romero, C., Rodr\u00edguez, C.M., Mart\u00ednez, L., and S\u00e1nchez-Lara, K. (2010). Association of Nutritional Status and Serum Albumin Levels with Development of Toxicity in Patients with Advanced Non-Small Cell Lung Cancer Treated with Paclitaxel-Cisplatin Chemotherapy: A Prospective Study. BMC Cancer, 10.","DOI":"10.1186\/1471-2407-10-50"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"PS9-20","DOI":"10.1158\/1538-7445.SABCS20-PS9-20","article-title":"Abstract PS9-20: Prospective Observational Study of Chemotherapy-Induced Alopecia after Sequential FEC+taxane and the Effects of Age in Breast Cancer Patients","volume":"81","author":"Fujii","year":"2021","journal-title":"Cancer Res."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1046\/j.1365-2354.2001.00272.x","article-title":"Hair and Cancer Chemotherapy: Consequences and Nursing Care\u2014A Literature Study","volume":"10","author":"Batchelor","year":"2001","journal-title":"Eur. J. Cancer Care"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"934","DOI":"10.3346\/jkms.2013.28.6.934","article-title":"Iron Plays a Certain Role in Patterned Hair Loss","volume":"28","author":"Park","year":"2013","journal-title":"J. Korean Med. Sci."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2133.1994.tb08547.x","article-title":"Hair Follicle Expression of 1,25-Dihydroxyvitamin D3 Receptors during the Murine Hair Cycle","volume":"131","author":"Reichrath","year":"1994","journal-title":"Br. J. Dermatol."},{"key":"ref_96","first-page":"487","article-title":"Hormones and hair growth","volume":"61","year":"2010","journal-title":"Hautarzt"},{"key":"ref_97","first-page":"5123","article-title":"Protection from Chemotherapy-Induced Alopecia by 1,25-Dihydroxyvitamin D3","volume":"52","author":"Jimenez","year":"1992","journal-title":"Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"615","DOI":"10.5966\/sctm.2012-0032","article-title":"1\u03b1,25-Dihydroxyvitamin D3 Modulates the Hair-Inductive Capacity of Dermal Papilla Cells: Therapeutic Potential for Hair Regeneration","volume":"1","author":"Aoi","year":"2012","journal-title":"Stem Cells Transl. Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.jqsrt.2004.11.017","article-title":"The Role of Iron and Zinc in Chemotherapy-Induced Alopecia","volume":"95","author":"Buyukavci","year":"2005","journal-title":"J. Quant. Spectrosc. Radiat. Transf."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ygyno.2003.12.013","article-title":"Selenium as an Element in the Treatment of Ovarian Cancer in Women Receiving Chemotherapy","volume":"93","author":"Sieja","year":"2004","journal-title":"Gynecol. Oncol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s10549-020-06005-6","article-title":"A Phase I Safety Study of Topical Calcitriol (BPM31543) for the Prevention of Chemotherapy-Induced Alopecia","volume":"186","author":"Lacouture","year":"2021","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.3390\/curroncol30040275","article-title":"Prevention and Treatment of Chemotherapy-Induced Alopecia: What Is Available and What Is Coming?","volume":"30","author":"Wikramanayake","year":"2023","journal-title":"Curr. Oncol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1186\/bcr3475","article-title":"A Genome-Wide Association Study of Chemotherapy-Induced Alopecia in Breast Cancer Patients","volume":"15","author":"Chung","year":"2013","journal-title":"Breast Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"x22","DOI":"10.1093\/annonc\/mdx655.022","article-title":"Incidence of Permanent Chemotherapy-Induced Alopecia among Breast Cancer Patients: A Five-Year Prospective Cohort Study","volume":"28","author":"Kang","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1634\/theoncologist.2018-0184","article-title":"Permanent Chemotherapy-Induced Alopecia in Patients with Breast Cancer: A 3-Year Prospective Cohort Study","volume":"24","author":"Kang","year":"2019","journal-title":"Oncologist"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"5709","DOI":"10.3390\/curroncol31090423","article-title":"Chemotherapy-Induced Alopecia by Docetaxel: Prevalence, Treatment and Prevention","volume":"31","author":"Perez","year":"2024","journal-title":"Curr. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jaad.2018.03.055","article-title":"Hair Disorders in Patients with Cancer","volume":"80","author":"Shapiro","year":"2019","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"426","DOI":"10.4103\/idoj.IDOJ_471_18","article-title":"A Descriptive Study to Analyze Chemotherapy-Induced Hair Loss and Its Psychosocial Impact in Adults: Our Experience from a Tertiary Care Hospital","volume":"10","author":"Saraswat","year":"2019","journal-title":"Indian Dermatol. Online J."},{"key":"ref_109","first-page":"2572","article-title":"Phase I and Preliminary Phase II Evaluation of Adriamycin (NSC 123127)","volume":"30","author":"Bonadonna","year":"1970","journal-title":"Cancer Res."},{"key":"ref_110","first-page":"3411","article-title":"Observation of Clinical Efficacy and Toxic and Side Effects of Pirarubicin Combined with Cytarabine on Acute Myeloid Leukemia","volume":"17","author":"Lv","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_111","first-page":"30","article-title":"Induction Therapy of Newly Diagnosed Acute Nonlymphocytic Leukemia with Idarubicin and Cytosine Arabinoside\u2014The Taiwan Experience","volume":"33","author":"Chen","year":"1996","journal-title":"Semin. Hematol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.ftd.0000158867.66994.91","article-title":"Association between Alopecia and Response to Chemotherapy in Patients with Hodgkin Lymphoma","volume":"27","author":"Elis","year":"2005","journal-title":"Ther. Drug Monit."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1054\/mehy.1998.0790","article-title":"Association between Alopecia and Response to Aggressive Chemotherapy in Patients with Hodgkin\u2019s Disease","volume":"53","author":"Lishner","year":"1999","journal-title":"Med. Hypotheses"},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Gaumond, S.I., Beraja, G.E., Kamholtz, I., Ferrari, L.M., Mahmoud, R.H., and Jimenez, J.J. (2025). Chemotherapy-Induced Alopecia in Ovarian Cancer: Incidence, Mechanisms, and Impact Across Treatment Regimens. Cancers, 17.","DOI":"10.3390\/cancers17030411"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/00001622-200203000-00012","article-title":"Cutaneous Toxicities of Cancer Therapy","volume":"14","author":"Alley","year":"2002","journal-title":"Curr. Opin. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1016\/S0959-8049(03)00319-8","article-title":"Carboplatin and Paclitaxol (Taxol) as an Induction Regimen for Patients with Biopsy-Proven Stage IIIA N2 Non-Small Cell Lung Cancer. an EORTC Phase II Study (EORTC 08958)","volume":"39","author":"Splinter","year":"2003","journal-title":"Eur. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","article-title":"Recommendations for the Prophylactic Management of Skin Reactions Induced by Epidermal Growth Factor Receptor Inhibitors in Patients with Solid Tumors","volume":"21","author":"Hofheinz","year":"2016","journal-title":"Oncologist"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1200\/JCO.22.02499","article-title":"Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients with Advanced Non-Small-Cell Lung Cancer","volume":"41","author":"Fukuoka","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_119","first-page":"100622","article-title":"A Comparative Study Evaluating the Quality of Life and Survival Outcomes in Patients Receiving Chemotherapy Versus Oral Tyrosine Kinase Inhibitor in the Third Line and Beyond Setting for Advanced NSCLC","volume":"5","author":"Noronha","year":"2024","journal-title":"JTO Clin. Res. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced Cardiotoxicity and Comparable Efficacy in a Phase III Trial of Pegylated Liposomal Doxorubicin HCl (CAELYX\/Doxil) versus Conventional Doxorubicin for First-Line Treatment of Metastatic Breast Cancer","volume":"15","author":"Wigler","year":"2004","journal-title":"Ann. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/S0959-8049(01)00050-8","article-title":"Randomised Phase II Trial of Pegylated Liposomal Doxorubicin (DOXIL\/CAELYX) versus Doxorubicin in the Treatment of Advanced or Metastatic Soft Tissue Sarcoma: A Study by the EORTC Soft Tissue and Bone Sarcoma Group","volume":"37","author":"Judson","year":"2001","journal-title":"Eur. J. Cancer"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.sder.2008.12.001","article-title":"Chemotherapy-Induced Alopecia","volume":"28","year":"2009","journal-title":"Semin. Cutan. Med. Surg."},{"key":"ref_123","first-page":"CD008792","article-title":"Combination versus Sequential Single Agent Chemotherapy for Metastatic Breast Cancer","volume":"2013","author":"Dear","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/DAD.0b013e3181fcfc25","article-title":"Permanent Alopecia after Systemic Chemotherapy: A Clinicopathological Study of 10 Cases","volume":"33","author":"Miteva","year":"2011","journal-title":"Am. J. Dermatopathol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1111\/j.1365-2133.2005.06469.x","article-title":"Permanent Alopecia after Busulfan Chemotherapy","volume":"152","author":"Tosti","year":"2005","journal-title":"Br. J. Dermatol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.jaad.2009.06.063","article-title":"Permanent Chemotherapy-Induced Alopecia: Case Report and Review of the Literature","volume":"63","author":"Tallon","year":"2010","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2010.03.020","article-title":"Permanent Chemotherapy-Induced Alopecia: A Review","volume":"64","author":"Palamaras","year":"2011","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/j.1365-2133.2009.09043.x","article-title":"Irreversible and Severe Alopecia Following Docetaxel or Paclitaxel Cytotoxic Therapy for Breast Cancer","volume":"160","author":"Prevezas","year":"2009","journal-title":"Br. J. Dermatol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e13395","DOI":"10.1111\/ecc.13395","article-title":"Permanent Hair Loss Associated with Taxane Chemotherapy Use in Breast Cancer: A Retrospective Survey at Two Tertiary UK Cancer Centres","volume":"30","author":"Chan","year":"2021","journal-title":"Eur. J. Cancer Care"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1001\/jamadermatol.2020.1867","article-title":"Association Between ABCB1 Genetic Variants and Persistent Chemotherapy-Induced Alopecia in Women with Breast Cancer","volume":"156","author":"Pita","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40265-018-0909-3","article-title":"Chemotherapy-Induced Neutropenia as a Prognostic and Predictive Marker of Outcomes in Solid-Tumor Patients","volume":"78","author":"Kasi","year":"2018","journal-title":"Drugs"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Furuya, Y. (2019). Early Neutropenia on Day 8 Treated with Adjuvant Docetaxel-Based Chemotherapy in Early Breast Cancer Patients: Putative Mechanisms within the Neutrophil Pool System. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0215576"},{"key":"ref_133","doi-asserted-by":"crossref","unstructured":"Watanabe, T., Yagata, H., Saito, M., Okada, H., Yajima, T., Tamai, N., Yoshida, Y., Takayama, T., Imai, H., and Nozawa, K. (2019). A Multicenter Survey of Temporal Changes in Chemotherapy-Induced Hair Loss in Breast Cancer Patients. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0208118"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1007\/s00520-018-4224-z","article-title":"Development of a Simplified Multivariable Model to Predict Neutropenic Complications in Cancer Patients Undergoing Chemotherapy","volume":"26","author":"Razzaghdoust","year":"2018","journal-title":"Support Care Cancer"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00520-023-08043-4","article-title":"Cost-Effectiveness of Granulocyte Colony-Stimulating Factors (G-CSFs) for the Prevention of Febrile Neutropenia (FN) in Patients with Cancer","volume":"31","author":"Aapro","year":"2023","journal-title":"Support Care Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:05:51Z","timestamp":1760029551000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/17\/7\/1163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,30]]},"references-count":136,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,4]]}},"alternative-id":["cancers17071163"],"URL":"https:\/\/doi.org\/10.3390\/cancers17071163","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,30]]}}}